Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead’s new HIV drug shows lower side-effects over longer term

[Reuters] – Drugmaker Gilead Sciences Inc said data from a late-stage study showed that its experimental drug, Genvoya, showed reduced side-effects compared with an older version of the drug in treating HIV-infected patients . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead’s new HIV drug shows lower side-effects over longer term Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015 Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment